BBLG Stock Price, Bone Biologics Corp Quote, Chart

Market Summary

USD1.88-0.32

Delayed

-14.55%

BBLG Stock Price

View Fullscreen

BBLG RSI Chart

BBLG Valuation

Market Cap

2.1M

Price/Earnings (Trailing)

-0.34

EV/EBITDA

0.18

Price/Free Cashflow

-0.22

MarketCap/EBT

-1.01

BBLG Price/Sales (Trailing)

BBLG Profitability

Return on Equity

-167.05%

Return on Assets

-159.88%

Free Cashflow Yield

-464.01%

BBLG Fundamentals

BBLG Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

75.74%

Earnings Growth (Qtr)

41.93%

Breaking Down BBLG Revenue

Last 7 days

-2.1%

Last 30 days

6.2%

Last 90 days

-51.5%

Trailing 12 Months

-95.2%

How does BBLG drawdown profile look like?

BBLG Financial Health

Current Ratio

23.32

BBLG Investor Care

Shares Dilution (1Y)

1481.27%

Diluted EPS (TTM)

1.77

Tracking the Latest Insider Buys and Sells of Bone Biologics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 13, 2023	walsh deina h	bought	5,120	0.64	8,000	chief financial officer
Sep 11, 2023	frelick jeff	bought	6,530	0.6874	9,500	chief executive officer
Sep 06, 2023	walsh deina h	bought	4,967	0.709571	7,000	chief financial officer
Aug 31, 2023	frelick jeff	bought	5,019	0.6605	7,600	chief executive officer
Mar 13, 2023	hankey don	sold	-	-	-500,137	chairman of the board
Oct 15, 2021	hankey don	acquired	2,495,240	5.24	476,190	chairman of the board
Oct 15, 2021	hankey don	gifted	-	-	-1,004,310	chairman of the board
Oct 15, 2021	hankey don	sold	-	-	-9,361,700	chairman of the board
Oct 15, 2021	hankey don	acquired	14,821,900	2.5	5,928,770	chairman of the board
Jan 02, 2020	hankey don	bought	195,000	1.00	195,000	chairman of the board

Which funds bought or sold BBLG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	new	-	568,236	568,236	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	246	3,515	9,052	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	78,810	78,810	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	414	414	-%
May 13, 2024	UBS Group AG	new	-	1,278	1,278	-%
May 13, 2024	CLEAR STREET LLC	new	-	2,000	2,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	-10.00	9.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-8,000	-	-%

Are Funds Buying or Selling BBLG?

Are funds buying BBLG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BBLG

No. of Funds

Unveiling Bone Biologics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 14, 2024	intracoastal capital, llc	9.99%	99,605	SC 13G
Feb 14, 2024	walleye capital llc	0.0%	0	SC 13G/A
Feb 14, 2024	ionic ventures, llc	6.5%	36,914	SC 13G/A
Feb 13, 2024	lind global fund ii lp	6.0%	34,180	SC 13G/A
Jan 02, 2024	sabby management, llc	2.52%	9,877	SC 13G/A
Dec 20, 2023	ionic ventures, llc	9.99%	55,190	SC 13G/A
Nov 27, 2023	intracoastal capital, llc	4.99%	224,445	SC 13G
Jun 26, 2023	lind global fund ii lp	6.5%	203,045	SC 13G
Mar 29, 2023	hankey don	41.7%	7,144,395	SC 13D/A
Feb 14, 2023	walleye capital llc	5.43%	830,245	SC 13G

Recent SEC filings of Bone Biologics Corp

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
Mar 15, 2024	8-K	Current Report
Mar 14, 2024	SC 13G	Major Ownership Report
Mar 06, 2024	8-K	Current Report
Mar 04, 2024	EFFECT	EFFECT
Mar 04, 2024	424B4	Prospectus Filed
Mar 01, 2024	8-K	Current Report
Mar 01, 2024	CORRESP	CORRESP
Feb 29, 2024	CORRESP	CORRESP
Feb 28, 2024	CORRESP	CORRESP

Peers (Alternatives to Bone Biologics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Bone Biologics Corp News

Latest updates

Bone Biologics Corp Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	2.7%	3,840	3,738	4,976	7,623	6,784	8,495	5,201	5,659	6,094	6,675	4,474	2,273	71.00	51.00	31.00	249	266	814	1,041	2,350	378
Current Assets	2.7%	3,840	3,738	-	-	-	8,495	-	-	-	-	-	-	-	-	31.00	249	266	814	1,041	2,350	378
Cash Equivalents	-100.0%	-	3,000	4,500	7,008	6,188	7,538	5,059	5,455	5,815	6,675	3.00	4.00	71.00	2.00	24.00	202	176	726	955	2,294	305
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26*	50*	74*	98*
Liabilities	-80.2%	165	831	1,183	1,930	4,011	2,548	799	4,394	7,989	11,583	15,178	14,620	14,195	12,471	11,898	-	-	-	9,639	9,525	9,834
Current Liabilities	-80.2%	165	831	1,183	1,930	4,011	2,548	-	-	-	100	-	-	-	12,471	578	11,631	11,122	10,786	9,639	525	1,271
Shareholder's Equity	26.4%	3,675	2,906	3,793	5,693	2,772	5,947	4,402	5,588	6,039	6,575	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.1%	-81,774	-80,900	-79,400	-77,400	-75,700	-71,960	-72,900	-71,634	-71,165	-70,475	-70,297	-69,788	-69,296	-67,637	-67,040	-66,509	-65,947	-65,022	-63,615	-62,144	-61,902
Additional Paid-In Capital	1.9%	85,449	83,815	83,152	83,129	78,426	77,907	77,245	77,212	77,194	77,051	55,160	55,142	55,142	55,142	55,142	55,096	55,062	55,022	54,991	54,962	50,620
Shares Outstanding	90.3%	1,016	534	392	392	2,088	64.00	43.00	43.00	43.00	43.00	12.00	12.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,163	-	-	-	4,403	-	-	-	1,260	-	-	-	-	520	-	-	-	6,005

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	38.1%	-1,300	-2,100	-2,500	-3,700	-1,300	-1,950	-395	-360	-860	-186	-277	-635	-127	-125	-72.23	-79.13	-149	-297	-474	-1,550	-928
Share Based Compensation	-25.9%	53.00	71.00	20.00	17.00	45.00	63.00	33.00	19.00	153	-	-	-	-	-	-	-	-	3.00	7.00	14.00	26.00
Cashflow From Financing	154.1%	1,504	592	-	4,452	-	-	-	-	-	6,859	277	569	199	123	75.00	77.00	128	120	500	1,000	700

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BBLG Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues
Operating expenses
Research and development	245,625	2,590,645
General and administrative	657,911	556,892
Total operating expenses	903,536	3,147,537
Loss from operations	(903,536)	(3,147,537)
Other income (expenses)
Change in fair value of warrant liability	37,311	(562,918)
Interest income	255	556
Total other income (expenses)	37,566	(562,362)
Net loss	$ (865,970)	$ (3,709,899)
Weighted average shares outstanding - basic	660,928	67,211
Weighted average shares outstanding - diluted	660,928	67,211
Loss per share - basic	$ (1.31)	$ (55.20)
Loss per share - diluted	$ (1.31)	$ (55.20)

BBLG Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 3,227,634	$ 3,026,569
Advances on research and development contract services	328,844	328,844
Prepaid insurance	273,096	372,350
Prepaid expenses	10,000	10,000
Total current assets	3,839,574	3,737,763
Total assets	3,839,574	3,737,763
Current Liabilities
Accounts payable and accrued expenses	146,186	360,662
Accrued legal settlement		414,989
Warrant liability	18,440	55,751
Total current liabilities	164,626	831,402
Total liabilities	164,626	831,402
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,016,489 and 534,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,016	534
Additional paid-in capital	85,448,860	83,814,785
Accumulated deficit	(81,774,928)	(80,908,958)
Total stockholders’ equity	3,674,948	2,906,361
Total liabilities and stockholders’ equity	$ 3,839,574	$ 3,737,763

About Bone Biologics Corp

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

CEO	Mr. Jeffrey Frelick
WEBSITE	bonebiologics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2

Bone Biologics Corp Frequently Asked Questions

What is the ticker symbol for Bone Biologics Corp? What does BBLG stand for in stocks?

BBLG is the stock ticker symbol of Bone Biologics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bone Biologics Corp (BBLG)?

As of Fri May 17 2024, market cap of Bone Biologics Corp is 2.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BBLG stock?

You can check BBLG's fair value in chart for subscribers.

What is the fair value of BBLG stock?

You can check BBLG's fair value in chart for subscribers. The fair value of Bone Biologics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bone Biologics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BBLG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bone Biologics Corp a good stock to buy?

The fair value guage provides a quick view whether BBLG is over valued or under valued. Whether Bone Biologics Corp is cheap or expensive depends on the assumptions which impact Bone Biologics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BBLG.